Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711814 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 611
- Enrollment target
NCT01711814 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 611 participants.
The verdict
NCT01711814, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 611 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of ASP015K in subjects with Rheumatoid Arthritis (RA) who have completed a preceding Phase 2 ASP015K RA study.
Interventions
- DRUG peficitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2012-09-26 |
| Est. Completion | 2016-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711814
The ClinicalTrials.gov registry entry for NCT01711814 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which peficitinib is the first listed.
NCT01711814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711814 about?
NCT01711814 is a clinical study titled "A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study". The purpose of this study is to evaluate the long-term safety and efficacy of ASP015K in subjects with Rheumatoid Arthritis (RA) who have completed a preceding Phase 2 ASP015K RA study.
What is the current status of trial NCT01711814?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 611 participants. The study started on 2012-09-26. Estimated completion is 2016-03-25.
What interventions are being tested in trial NCT01711814?
The interventions under investigation include: peficitinib (DRUG).
Who is sponsoring clinical trial NCT01711814?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.